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Using a newly developed Plasmodium vivax merozoite surface protein 1 gene (Pvmsp1) heteroduplex tracking assay, we geno-
typed 107 P. vivax infections in individuals from Cambodia, 45 of whom developed recurrent parasitemia within 42 days. The
majority of isolates were polyclonal, but recurrent parasitemias displayed fewer variants compared to initial parasitemias. Two
Pvmsp1 gene variants occurred more frequently in the initial genotypes of those who developed recurrent parasitemia, repre-
senting the first time P. vivax variants associated with a higher risk of relapse have been described.
Plasmodium vivax is the most prevalent malaria species outsideAfrica and causes significant morbidity in the developing
world. It uniquely maintains its transmission in a wide range of
latitudes by causing periodic relapses through reactivation of liver
stage parasites called hypnozoites. Being able to identify those at
risk for relapse has the potential to guide clinical management and
drug policy (4, 9). However, studying P. vivax relapse in areas of
endemicity has been difficult because genotyping methods have
not been able to precisely differentiate relapse from new infection
or recrudescence due to treatment failure.
It is known that P. vivax infections are frequently polyclonal,
even in relatively low-transmission settings (3, 7). We sought to
exploit this complexity of infection to better describe genotypic
patterns of relapsing parasites and search for genotypic variants
associated with relapse. To do this, we developed a P. vivax het-
eroduplex tracking assay (HTA) to evaluate pretreatment and re-
current parasitemias from 107 patients treated with chloroquine
monotherapy in Chumkiri, Cambodia, 45 of whom developed
recurrent P. vivax infection within 42 days of therapy.
HTAs have previously been shown to be more sensitive than
nested PCR for determining the multiplicity of infection (MOI) in
malaria infections due to their ability to detect both sequence and
size polymorphisms (11). We developed an HTA targeting the P.
vivax merozoite surface protein 1 gene (Pvmsp1), a highly poly-
morphic gene that is commonly used for genotyping P. vivax ma-
laria. The probe was constructed as previously described, using
primers based on a previously published assay and genomic DNA
obtained from MR4 (Nicaragua strain, catalog no. MRA-340;
MR4, Manassas, VA) (10, 11) (GenBank accession number
JN674534). Pvmsp1 PCR products were amplified using the same
primers from patient DNA that was extracted from filter paper
blood spots. HTAs were performed as previously described. All
gels were run with probe alone and nontemplate control lanes.
Patient samples were acquired from a clinical trial that enrolled
persons 1 year old presenting with uncomplicated P. vivax ma-
laria to the Chumkiri health center in Kampot Province, Cambo-
dia, between August 2006 and December 2007 (14). In this study,
subjects were given a total dose of 25 mg/kg of body weight of
chloroquine base over 3 days with directly observed therapy, fol-
lowed with weekly blood smears until day 42. Antirelapse therapy
with primaquine was not given, as this is not part of Cambodian
national guidelines. The 45 subjects who developed recurrent P.
vivax infection during the 42-day follow-up were retreated with
chloroquine. Chumkiri is a low-transmission area, with most of
the malaria acquired in the surrounding mountains and forest.
Thus, these patients had a low, but not negligible, chance of rein-
fection.
Molecular analysis was done on 107 enrollment (day 0)
samples and 44 available recurrent P. vivax samples collected
on the day of recurrence. HTA bands were considered unique
Pvmsp1 variants if they were not in the single-stranded probe or
probe homoduplex lanes (Fig. 1). Multiplicity of infection was
determined by counting the number of unique variants in each
isolate. To assign identities to individual variants, the relative
migration distance (Rf) was calculated for each variant by di-
viding the distance migrated by the band by the distance mi-
grated by the probe homoduplex. Rf units were divided among
20 bins of 0.05 Rf units (8).
The Pvmsp1 HTA detected a high proportion of polyclonal
infections among the clinical samples. Among the day 0 isolates,
89/107 (83%) displayed multiple heteroduplex bands, with a
range of 1 to 7 msp1 variants detected within a single isolate. The
median MOI was 3, with a mean MOI of 2.82. A total of 16 distinct
variants were identified, with six common variants accounting for
88% of the total (n  302 bands). The different combinations of
these variants revealed 64 unique genotypes among the 107 iso-
lates.
Among the 44 available paired samples from recurrences, there
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was a high degree of genetic relatedness between the initial and
recurrent samples. In 86% (38/44) of the pairs, at least half of the
variants detected in the recurrent parasitemia were also detected
in the initial parasitemia (examples in Fig. 1). Since none of the
recurrences occurred prior to day 28, when failure due to chloro-
quine resistance is expected (15), the genetic relatedness of these
38 pairs suggests that they represent relapses or less likely, recru-
descence. Analysis of these 38 pairs showed a significant reduction
in MOIs between initial and recurrent infections (mean MOIs of
3.13 and 2.26, respectively; P  0.001 by a paired t test). This
suggests that relapsing genotypes arising from hypnozoites are still
often polyclonal but more restricted in their multiclonality.
When the genotypes from initial infections of 45 “relapsers”
and 62 “nonrelapsers” (those who did and did not develop recur-
rent parasitemia within 42 days, respectively) were compared, cer-
tain variants appeared to be associated with subsequent relapse
(Fig. 2a). Specifically, variants with Rfs of 0.30 and 0.35 were 2.4
and 5.0 times more likely, respectively, to appear in the initial
genotype of a relapsing infection (95% confidence intervals [CI]
of 1.3 to 4.4 and 2.0 to 12.4, respectively; P values of 0.003 and
0.001, respectively, by Fisher’s exact test) (Fig. 2b). The presence
of either of these two variants in an initial genotype “predicted”
relapse with 78% sensitivity and 73% specificity. The presence of
an Rf of 0.35 alone was 92% specific for predicting relapse within
42 days in our cohort. In contrast, a variant with an Rf of 0.10 was
less likely to be associated with a relapsing infection (risk ratio
[RR], 0.5; 95% CI, 0.4 to 0.8; P  0.001).
On average, subjects who developed recurrent parasitemia
within 42 days were younger than those who did not (means of 19
years of age in relapsers and 22 years of age in nonrelapsers; P 
0.02 by a t test) but did not otherwise differ from their nonrelaps-
ing counterparts in terms of gender, baseline parasitemia, or par-
asite clearance times. They likewise demonstrated no difference in
MOI at enrollment (mean MOIs of 2.89 in relapsers and 2.76 in
nonrelapsers).
These data illustrate the novel finding that different parasite
subpopulations may display different propensities for relapse. Re-
lapse patterns of P. vivax parasites are known to differ between
broad geographic regions, with tropical strains relapsing more
frequently and at shorter 3- to 4-week intervals compared to the
longer intervals (up to 8 to 9 months later) seen in strains from
subtropical/temperate zones (1). This is thought to reflect envi-
ronmental adaptations based on the availability of mosquito vec-
tors. Our findings support a genetic basis to relapse, with certain
parasite variants possibly being more susceptible to the triggers
that reactivate hypnozoites or more likely to remain in the hypno-
zoite form after sporozoite inoculation, thus devoting a greater
fraction of their numbers to future relapse (5). Alternatively, these
variants may have evolved a better mechanism for immune eva-
sion in the primary infection, allowing them to once again become
patent in a relapsed infection.
The main limitation to our study is our reliance on samples
from an area of P. vivax endemicity in which it is not possible to
FIG 1 Pvmsp1 HTAs for P. vivax isolates from selected Cambodian subjects
with relapsing infections. Bands that were not in the single-stranded probe or
probe homoduplex lanes were considered unique Pvmsp1 variants. Paired ini-
tial and recurrent infections are shown, with “R” indicating the recurrent
sample. The variant with an Rf of 0.35 is indicated by a thick arrow in both gels.
FIG 2 (a) Frequency of Pvmsp1 variants in relapsing (n  45) and nonrelaps-
ing (n  62) P. vivax malaria infections in 107 Cambodian patients. The
frequencies of variants with Rfs of 0.10, 0.30, and 0.35 were significantly dif-
ferent between relapsing and nonrelapsing strains. (b) Risk ratios for the asso-
ciation of Pvmsp1 variants with relapsing infection. Out of the six common
variants identified by the Pvmsp1 HTA, variants with Rfs of 0.35 and 0.30 were
positively associated with relapsing infections, while an Rf of 0.10 was associ-
ated with nonrelapsing infections. Error bars represent the 95% confidence
intervals of the relative risk ratio.
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prove definitively that a recurrent infection is a relapse, recrudes-
cence, or reinfection. Relapses are expected to comprise a signifi-
cant portion of the recurrences in this study, as primaquine was
not given at enrollment, and the majority of recurrences (43/45)
occurred between day 35 and day 42, a pattern which is consistent
with previously reported relapse intervals in this region (12).
There were no recurrent parasitemias prior to day 28 in the co-
hort, suggesting a limited role for recrudescence among the recur-
rences. Indeed, chloroquine resistance has not been reported from
this study area to date. Finally, the incidence of malaria in Chum-
kiri based on passive case detection at health centers was approx-
imately 15 cases/1,000 person-years in 2008, suggesting that rein-
fection should be relatively uncommon (Cambodian National
Malaria Center, unpublished data). Recurring genotypes with
fewer than two shared variants and multiple novel variants, sug-
gestive of reinfection, made up just 14% (6/44) of recurrent infec-
tions, a rate that is similar to the estimated Plasmodium falciparum
reinfection rate of 13% (4/31) reported in the same trial that was
based on standard PCR genotyping methods for P. falciparum
(14).
Previous studies on relapsing P. vivax infections that were able
to compare initial and recurrent genotypes from subjects who had
left areas of P. vivax endemicity have concluded that the genotypes
of relapsing parasites differ from those of the initial infection in
over half of cases (6, 13). However, the nested PCR and microsat-
ellite genotyping methods employed in these studies are limited in
their ability to detect minority variants and fully assess polyclonal
infections. Our strategy of uncovering multiple variants at a single
gene locus and comparing these complex mixtures of variants
across time affords a greater appreciation of the relatedness of
initial and relapsing parasite populations. Data obtained using
this method suggest that P. vivax relapses arise from the activation
of multiple and diverse hypnozoites, not single hypnozoite clones
as has been postulated (2).
Using an HTA, we have shown that clinical P. vivax infections
are often composed of complex mixtures of multiple variants, and
some variants are more prone to relapse than others. Having a
greater appreciation of the polyclonality of P. vivax infections may
help us recognize genotypic patterns of relapsing parasite popula-
tions and perhaps even identify individuals at greater risk for re-
lapsing malaria who would benefit from terminal prophylaxis
with primaquine.
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